Physicians' Academy for Cardiovascular Education

Atrial fibrillation

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

Screening using a smartphone-app more than doubles detection rate of AF

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD

Atrial fibrillation: From risk prediction to clinical outcomes

10' education - Apr. 6, 2022 - Prof. Stefan Hohnloser, MD

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD

Screening for AF with irregular heart rhythm detection by Fitbit wearables

3' education - Nov. 14, 2021 - Steven Lubitz, MD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

Initiating digoxin in AF patients associated with early hazard of sudden death

3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Tailoring oral anticoagulation in elderly patients with AF

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

Outstanding questions and ongoing studies on the use of NOACs

3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Where are we with HF patients with AF?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD
In a subpopulation of patients with rheumatic heart disease and AF, the effect of rivaroxaban vs. VKA was examined for the composite outcome of stroke, systemic embolism, MI and death from vascular or unknown cause.

ESC 2022 In a subpopulation of patients with rheumatic heart disease and AF, the effect of rivaroxaban vs. VKA was examined for the composite outcome of stroke, systemic embolism, MI and death from vascular or unknown cause.

Predictive performance of risk scores for ischemic stroke in AF

Literature - Sep. 12, 2022 - Van der Endt VHW, et al. - Europace. 2022

Although the newer risk scores tended to have better predictive abilities than the conventional scores, research on external validation and calibration is required to confirm this.

Screening using a smartphone-app more than doubles detection rate of AF

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD
eBRAVE-AF tested the efficacy of a digital screening strategy using ordinary smartphones for detecting treatment-relevant AF in an elderly population in a head-to-head comparison with usual care.

ESC 2022 eBRAVE-AF tested the efficacy of a digital screening strategy using ordinary smartphones for detecting treatment-relevant AF in an elderly population in a head-to-head comparison with usual care.

Smartphone-based screening increases detection rate of AF

News - Aug. 28, 2022

ESC 2022 A digital screening strategy using normal smartphones more than doubled the detection rate of AF.

E-learning Updates in anticoagulation management in AF and VTE

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Three speakers will provide guidance and insights on the treatment of patients with atrial fibrillation or venous thromboembolism in clinical practice. Watch the presentations and answer the questions! NEW: Content of the course also available as text

Atrial fibrillation or flutter increases risk of adverse outcomes in HFpEF

Literature - May 17, 2022 - Cikes M et al. - JACC Heart Fail. 2022

If HFpEF patients also have atrial fibrillation and/or flutter, they are at increased risk of HF hospitalization or CV death, as shown by a post-hoc analysis of the PARAGON-HF trial.

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD
Prof. Storey guides us through the ESC guidelines for the prevention of thromboembolic events in patients with atrial fibrillation.

Prof. Storey guides us through the ESC guidelines for the prevention of thromboembolic events in patients with atrial fibrillation.

Factor XIa inhibitor lowers bleeding rate compared with NOAC in AF patients

News - Apr. 11, 2022

ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.

Atrial fibrillation: From risk prediction to clinical outcomes

10' education - Apr. 6, 2022 - Prof. Stefan Hohnloser, MD
Prof. Hohnloser talks about innovations in screening for AF. He also gives an overview of clinical outcomes with anticoagulation therapy in AF and discusses updates in recent AF guidelines.

Prof. Hohnloser talks about innovations in screening for AF. He also gives an overview of clinical outcomes with anticoagulation therapy in AF and discusses updates in recent AF guidelines.

Effectiveness and safety of anticoagulant therapy in patients with AF at low stroke risk

Literature - Mar. 21, 2022 - Komen JJ et al. - Eur Heart J. 2022

The results of an observational study suggest that treatment with DOAC may be associated with a positive net clinical benefit compared with VKA and no anticoagulation treatment in patients with AF at low stroke risk.

Anticoagulation reversal in patients with acute bleeding during oral factor Xa inhibitor therapy

Literature - Jan. 17, 2022 - Benz AP et al. - Thromb Haemost. 2022

Andexanet alfa specifically binds and sequesters factor Xa inhibitors. A study investigated the efficacy and safety of andexanet alfa in patients on edoxaban with acute major bleeding.

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD
In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.